Vaccine has published Pharmerit's recent research in pneumonia

Pharmerit is pleased to report that its research in pneumococcal vaccination has been published in Vaccine. The manuscript describes a transmission dynamic epidemiologic model characterizing the decline in pneumococcal disease incidence in vaccinated and unvaccinated populations in the United States after wide-spread infant and toddler vaccination with the 7-valent pneumococcal conjugate vaccine (link to PDF)

Recent clinical findings in Rheumatoid Arthritis captured in Pharmerit's health economic model

Recent clinical findings, reported in the Guardian, indicated that early treatment of aggressive rheumatoid arthritis (RA) with an anti-TNF agent caused on-going underlying joint damage to be almost completely halted. 

This element of underlying latent disease progression has been incorporated in Pharmerit's RA health economic model recently developed by Professor Ben van Hout, PhD, Scientific Director of Pharmerit. This RA model incorporates several other additional disease characteristics, providing a template to assess the value of treatments which target more than one aspect of RA disease activity. A cost-effectiveness analysis using the RA model was presented at the 2009 EULAR conference in Copenhagen, Denmark.